What Is Milo Biotechnology?

Milo Biotechnology is company developing a therapy that increases muscle strength or decrease the rate of muscle atrophy for the treatment of muscular disorders.

The company’s technology, a gene therapy-based up-regulation of the muscle-strengthening follistatin protein, was developed at and is exclusively licensed from Nationwide Children’s Hospital (Ohio, U.S.A.).

In 2014 the therapy completed a Phase I/II clinical study in Becker Muscular Dystrophy establishing initial safety and efficacy.

Recent News

03Dec

Milo Biotechnology Announces Patent Issuance

0 Comments
Cleveland and Columbus, OH, December 3, 2014–Milo Biotechnology, which is applying its follistatin gene therapy in three clinical programs, today... Read More →
10Nov

The Duchenne Alliance commits $500,000 to Dr. Jerry Mendell and Milo Biotechnology to fund first Duchenne Follistatin Gene Therapy Trial

0 Comments
Columbus and Cleveland, OH, November 10, 2014– The International Duchenne Alliance announced today that it will allocate $500,000 to Dr.... Read More →
Back to Top